No abstract

Background: The aim of the study was to determine the cumulative incidence of BM, predictive factors of BM, and survival from diagnosis of BM in a cohort of breast cancer patients in a single institution. Patients and Methods: We collected data from a cohort of 793 breast cancer patients between January 2000 and December 2005 in our institution. Variables recorded include age at diagnosis, hormonal receptor status (HRS), human epidermal growth factor receptor 2 status (HER2), histological grade, T stage and N stage. We analyzed the 5 and 10-year cumulative incidence of BM. Time to detection of BM and survival from BM were estimated using Kaplan-Meier method. Cox regression model was used to analyze the variables associated with time to BM Results: With a median follow-up of 100 months, 49 patients went on to develop BM. The overall 5 and 10 year cumulative incidence of BM were 4.9% and 8.2% respectively. The table shows the 5 and 10 year cumulative incidence and hazard ratio (HR) of the predictive factors for the development of BM in the univariable analysis. Including all significant variables in the model, HER2 positive and node positive patients had an increase risk of BM, HR 2.46 (95% CI: 1.22–4.95) and 2.51 (95% CI: 1.19–5.29) respectively. HRS positive patients had a decreased risk of developing BM, HR 0.44 (95% CI: 0.21–0.89). Median survival from BM of HER2 positive and HER2 negative patients was 9 and 3 months respectively (p = 0.015), and 6 and 1 month for HRS positive and negative respectively (p = 0.02) Conclusion: Predictive factors independently associated with a high risk of BM in our cohort are HER2 positivity and positive nodes. Patients with positive HRS have a decreased risk of BM. Survival time following BM is poor. HER2 positive and HRS positive patients have a better survival than HER2 negative and HRS negative patients. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-12-08.